doctor-patient

For Healthcare Professionals

 

This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) who are interested in information on TECENTRIQ®. If you are a US healthcare professional click hereopens in a new tab

 

The product has received EMA approval. The registration status and approved product labels of TECENTRIQ® may not be the same in different countries. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details.

 

This website has been updated according to the latest EMA approval in February 2021.

Bladder

TECENTRIQ

 

MAKE AN ENDURING
CONNECTION

Although cisplatin-based chemotherapy remains the recommended frontline option for cisplatin-eligible patients with mUC, [i] immunotherapy with TECENTRIQ is a treatment option in the first-line setting for cisplatin-ineligible patients whose profile have a PD-L1 expression ≥5%.3

Urothelial cancer is an aggressive malignancy with poor prognosis

In the metastatic setting, urothelial cancer is associated with a 5-year survival of just 5%.

FOR INFORMATION ON TECENTRIQ SAFETY OR EFFICACY IN FIRST- OR SECOND-LINE mUC, CLICK A LINK BELOW

First-line mUC

Second-line mUC

TECENTRIQ is approved for a broad range of patients with locally advanced or mUC3

TECENTRIQ indications

TECENTRIQ as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC):3

  • After prior platinum containing chemotherapy, or
  • Who are considered cisplatin ineligible, and whose profile have a PD-L1 expression ≥5%
Locally advanced or metastatic urothelial carcinoma patients eligible for TECENTRIQ

PD-L1, programmed death-ligand 1.

 

In the IMvigor210 and 211 clinical trials, locally advanced or mUC patients eligible for TECENTRIQ and treated with neoadjuvant or adjuvant chemotherapy had disease progression within 12 months of treatment.

IMvigor210: A Phase 2 efficacy trial in first-line mUC4

A Phase 2, two-cohort study in patients with locally advanced or mUC (N=429) who were ineligible for cisplatin (n=119) or had received prior platinum therapy (n=310) received TECENTRIQ until unacceptable toxicity or disease progression. Primary endpoints included ORR and DOR. 

IMvigor210 STUDY DESIGN

TECENTRIQ: the first cancer immunotherapy approved in first-line PD-L1+ cisplatin-ineligible mUC

TECENTRIQ delivers a durable response in first-line and pre-treated mUC

What this means for patients with mUC

“The results of SAUL support the use of atezolizumab in urinary tract carcinoma, including in patients with limited treatment options.”

 

Prof. Axel Merseburger

 

“I have got quality of life now…. I plan a summer holiday”

 

Dave, patient suffering from bladder cancer 

TECENTRIQ has demonstrated a number of ground-breaking milestones:

The first cancer immunotherapy combination in first-line advanced TNBC3,9

The first cancer immunotherapy approved in advanced bladder cancer3,5,10

The first and only treatment approved in more than a decade to demonstrate superior survival in first-line HCC3,11

CONNECTING YOU WITH YOUR PATIENTS

At Roche, we believe in a shared purpose in improving the care and treatment of patients living with difficult to treat cancers. We understand and empathise with the demands you face managing the needs of these patients.

Roche is committed to exploring new treatment options to individualise treatment and meet patients’ needs. TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to exploring new combinations to improve patient outcomes (ref. SmPC). 

TECENTRIQ is an anti PD-L1 cancer immunotherapy that specifically targets PD-L1 on tumour and tumour-infiltrating immune cells across a broad range of solid tumours. TECENTRIQ offers a pioneering, targeted treatment with proven efficacy and an acceptable tolerability profile (ref. SmPC). Please see the specific indications for more information.